Introduction {#s1}
============

IL-1 family includes ten known members, all of which are characterized by gene structure, predicted three-dimensional fold, processing, receptor, signal transduction pathway and pro-inflammatory properties \[[@B1]\]. IL-18, also known as interferon-gamma inducing factor (IGIF), is a member of the IL-1 super-family \[[@B2]\]. IL-18 is secreted by a wide range of cells, including T and B lymphocytes, and antigen-presenting cells (APCs), including activated monocytes, macrophages, Kupffer cells, Langerhans cells, and NK cells \[[@B3]-[@B5]\]. IL-1 beta converting enzyme can convert IL-18 to a mature biologically active 18.3-kDa form through cleavage of the propeptide. IL-18 binds to the cell through a specific receptor, IL-18R, belonging to the toll-like receptor family \[[@B6]\]. IL-18 plays a central role in inflammation and immune response, and is generally acknowledged as a key defense cytokine against infectious agents. Because immune stimulating effects of IL-18 have also antineoplastic properties, it was tempting to propose IL-18 as a novel adjuvant therapy against cancer \[[@B7]\]. A number of single nucleotide polymorphisms (SNPs) of IL-18 gene have been identified and investigated \[[@B8]\]. There are three SNPs in the promoter region of IL-18 gene: -137, -607 and -656, relative to the transcriptional start site, which may alter the expression of IL-18 \[[@B9]\]. The C to A substitution at position −607 disrupts a consensus cAMP-responsive element protein-binding site, causing altered transcription factor binding and gene expression \[[@B9]\]. Several observational studies have investigated the association between -607 C/A polymorphism of IL-18 gene promoter and cancer risk; however, the results were inconsistent. For example, some studies found that -607 C/A polymorphism of IL-18 gene promoter was associated with increased risk of nasopharyngeal carcinoma \[[@B10]\] and lung cancer \[[@B11]\]. However, other studies found there was no association between -607 C/A polymorphism of IL-18 gene and risk of breast cancer \[[@B12]\] or head and neck squamous cell carcinoma \[[@B13]\]. Therefore, we performed a meta-analysis to derive a more precise estimation of the association to help us better understand the relationship between -607 C/A polymorphism of IL-18 gene and risk of cancer.

Methods {#s2}
=======

Identification of studies {#s2.1}
-------------------------

Comprehensive searches were carried out using PubMed, EMBASE, and China National Knowledge Infrastructure (CNKI) databases between January 1966 and February 2013. There were no restriction of origin and languages. Search terms included: \"Interleukin-18\" or \"IL-18\" or \"rs1946518\" in combination with "polymorphism" or "variant" and ''cancer'' or ''neoplasm'' or ''malignancy''. The reference list of each comparative study and previous reviews were manually examined to ﬁnd additional relevant studies.

Inclusion and exclusion criteria {#s2.2}
--------------------------------

Studies were selected according to the following inclusion criteria: (i) case-control studies; (ii) investigating the association between IL-18 rs1946518 (C\>A) SNP and cancer risk; (iii)cancers diagnosed by histopathology; (iiii) providing detail genotype frequencies. Studies without detail genotype frequencies were excluded. Titles and abstracts of searching results were screened and full text papers were further evaluated to confirm eligibility. Two reviewers (WM and ZXY) independently selected eligible trials. Disagreement between the two reviewers was settled by discussing with the third reviewer(WL).

Data extraction {#s2.3}
---------------

In the present study, the following characteristics were collected by two reviewers (WM and LY) independently using a purpose-designed form: name of first author, publishing time, country where the study was conducted, ethnicity, cancer types, source of control, number of cases and controls, genotype frequency in cases and controls. Different ethnicity descents were categorized as Asian, Caucasian, and African. Cancer types were classified as prostate cancer, esophageal cancer, nasopharyngeal carcinoma, colorectal cancer, breast cancer, cervical cancer, and other cancers (bladder cancer, renal cell carcinoma, head and neck squamous cell carcinoma, lung cancer, stomach cancer, ovarian cancer, choriocarcinoma, and oral cancer). Eligible studies were defined as hospital-based (HB) and population-based (PB) according to the control source.

Statistical analysis {#s2.4}
--------------------

Chi-square based Q test was used to check the statistical heterogeneity between studies, and the heterogeneity was considered significant when p\<0.10 \[[@B14]\]. The fixed-effects model (based on Mantel-Haenszel method) and random-effects model (based on DerSimonian-Laird method) were used to pool the data from different studies. The fixed-effects model was used when there was no significant heterogeneity; otherwise, the random-effects model was applied \[[@B15]\]. The association strength between -607 C/A (rs1946518) polymorphism and cancer risk was measured by odds ratio (OR) with 95% confidence intervals (95% CI). The estimates of pooled ORs were achieved by calculating a weighted average of OR from each study. A 95% CI was used for statistical significance test and a 95% CI without 1 for OR indicating a significant increased or reduced cancer risk. The pooled ORs were calculated for homozygote comparison (AA versus CC), heterozygote comparison (CA versus CC), dominant (CA/AA versus CC) and recessive (AA versus CC/CA) modes, assuming dominant and recessive effects of the variant A allele, respectively. Subgroup analyses were performed according to (i) cancer types, (ii) ethnicities, (iii) source of control, and (iiii) sample size, to examine the impact of these factors on the association. To test the robustness of association, sensitivity analysis were carried out by excluding studies one-by-one and analyzing the effect size for all of rest studies. Cumulative meta-analysis was also performed to identify the change in trend of reporting risk over time. In cumulative meta-analysis, studies were chronologically ordered by publication year, then the pooled RRs were obtained at the end of each year. To better investigate the possible sources of between-study heterogeneity, a meta-regression analysis was performed \[[@B16]\]. Publication bias was assessed using Begg and Mazumdar adjusted rank correlation test and the Egger regression asymmetry test \[[@B17],[@B18]\]. HWE(Hardy-Weinberg equilibrium) was tested by Pearson's X^2^ test (P\<0.05 means deviated from HWE). All analyses were performed using Stata version 11.0 (StataCorp, College Station, TX).

Results {#s3}
=======

Search results and characteristics of studies included in the meta-analysis {#s3.1}
---------------------------------------------------------------------------

A total of 792 citations were identified during the initial search (shown in [Figure 1](#pone-0076915-g001){ref-type="fig"}). On the basis of the title and abstract, we identified 24 papers. After detailed evaluation, one study was excluded for incorrect data, and two studies were excluded for having not presented -607 C/A polymorphisms. In the study reported by Haghshenas MR and colleagues \[[@B19]\], they investigated rs1946518 polymorphisms and colorectal cancer, as well as stomach cancer, and the data was presented separately, thus both of them were considered as a separate study in this meta-analysis. At last, 22 case-control studies \[[@B10]-[@B13],[@B19]-[@B35]\], including 4100 cancer cases and 4327 controls, were included in the meta-analysis(Baseline data and other details are shown in [Table 1](#pone-0076915-t001){ref-type="table"}). 16 eligible studies were conducted in Asia \[[@B11]-[@B13],[@B19],[@B21],[@B23]-[@B27],[@B29],[@B30],[@B32],[@B34],[@B35]\], five in Europe \[[@B10],[@B20],[@B28],[@B31],[@B33]\], and the remaining one in Africa \[[@B22]\]. There were five studies including more than 500 participants and the others had a sample size less than 500 participants. Genotype distribution of controls in all studies was consistent with HWE.

![Flow diagram of the study selection process.](pone.0076915.g001){#pone-0076915-g001}
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###### Characteristics of studies included in the meta-analysis.

  First Author     Year   Country   Ethnicity   Control            No. of Cases   No. of Controls   Cancer Type                Sample size   Cases               Controls         
  ---------------- ------ --------- ----------- ------------------ -------------- ----------------- -------------------------- ------------- ------- ----- ----- ---------- ----- -----
                                                                                                                                             AA      CA    CC    AA         CA    CC
  Liu JM           2013   China     Asian       Population Based   375            400               Prostate Cancer            Large         103     172   100   110        196   94
  Babar M          2012   UK        Caucasian   Population Based   1070           194               Esophageal Cancer          Large         178     508   384   36         75    83
  Du B             2012   China     Asian       Hospital Based     150            180               Nasopharyngeal Carcinoma   Small         34      80    36    40         93    47
  Guo JY           2012   China     Asian       Hospital Based     170            160               Colorectal Cancer          Small         49      85    36    42         76    42
  Taheri M         2012   Iran      Asian       Population Based   72             93                Breast Cancer              Small         11      32    29    8          45    40
  Saenz-Lopez P    2010   Spain     Caucasian   Population Based   154            500               Other Types                Large         19      76    59    73         261   166
  Asefi V          2009   Iran      Asian       Hospital Based     111            212               Other Types                Small         15      53    43    29         101   82
  Farjadfar A      2009   Iran      Asian       Hospital Based     73             97                Other Types                Small         13      45    15    11         46    40
  Haghshenas MR    2009   Iran      Asian       Population Based   142            311               Colorectal Cancer          Small         15      72    55    48         144   119
  Haghshenas MR    2009   Iran      Asian       Population Based   87             311               Other Types                Small         16      40    31    48         144   119
  Khalili-Azad T   2009   Iran      Asian       Population Based   200            206               Breast Cancer              Small         33      103   64    33         97    76
  Nong LG          2009   China     Asian       Population Based   250            270               Nasopharyngeal Carcinoma   Large         71      132   47    68         133   69
  Samsami DA       2009   Iran      Asian       Hospital Based     85             158               Other Types                Small         12      51    22    26         75    57
  Farhat K         2008   Tunisia   African     Population Based   163            164               Nasopharyngeal Carcinoma   Small         28      94    41    34         77    53
  Kashef MA        2008   Iran      Asian       Population Based   19             103               Other Types                Small         3       10    6     16         54    33
  Qi T             2008   China     Asian       Hospital Based     50             50                Cervical Cancer            Small         28      17    5     9          24    17
  Liu Y            2007   China     Asian       Hospital Based     265            280               Prostate Cancer            Large         72      143   50    78         137   65
  Nikiteas N       2007   Greece    Caucasian   Population Based   84             89                Colorectal Cancer          Small         18      47    19    22         32    35
  Vairaktaris E    2007   Germany   Caucasian   Population Based   149            89                Other Types                Small         28      66    55    22         32    35
  Wei YS           2007   China     Asian       Hospital Based     235            250               Esophageal Cancer          Small         64      123   48    67         124   59
  Yang HL          2007   China     Asian       Population Based   107            80                Cervical Cancer            Small         24      50    33    36         26    18
  Pratesi C        2006   Italy     Caucasian   Population Based   89             130               Nasopharyngeal Carcinoma   Small         21      42    26    23         64    43

Main results {#s3.2}
------------

Given that the P value of Q-tests was less than 0.10 under the allelic, homozygous, recessive, and dominant genetic models, the random-effects model was used. By contrast, the P value of Q-tests was more than 0.10 under the heterozygous genetic model (P for heterogeneity = 0.219); thus, the fixed-effects model was adopted. Significant associations between -607C/A polymorphisms in IL-18 gene promoter and cancer risk were observed in the heterozygous model (CA vs CC:OR =1.221, 95% CI: 1.096, 1.360; P~heterogeneity~=0.219, [Figure 2](#pone-0076915-g002){ref-type="fig"}) and the dominant model (AA/CA vs. CC:OR =1.203, 95% CI: 1.057, 1.369; P~heterogeneity~=0.064, [Figure 3](#pone-0076915-g003){ref-type="fig"}) in this meta-analysis. However, no significant association between -607C/A polymorphisms in IL-18 gene promoter and cancer risk was observed under the allelic model(A vs C:OR =1.088, 95% CI: 0.987,1.200; P~heterogeneity~=0.003), homozygous model(AA vs CC:OR =1.139, 95% CI: 0.948, 1.369; P~heterogeneity~=0.023), and recessive model (AA vs. CC/CA: OR =0.995, 95% CI: 0.851, 1.163; P~heterogeneity~=0.025) (shown in [Table 2](#pone-0076915-t002){ref-type="table"}).

![Forest plot of heterozygote comparison for overall comparison (CA vs. CC).](pone.0076915.g002){#pone-0076915-g002}

![Forest plot of dominant model for overall comparison (CA/AA vs. CC).](pone.0076915.g003){#pone-0076915-g003}
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###### Stratified analyses of the -607C/A polymorphisms in IL-18 gene promoter with cancer risk.

                             A vs. C   AA vs. CC               CA vs. CC   AA vs. CC/CA   AA/CA vs. CC                                                                                                                             
  -------------------------- --------- ----------------------- ----------- -------------- ---------------------- --------- ---- ----------------------- ------- ---- ---------------------- --------- ---- ----------------------- -------
  Overall                    23        1.088 (0.987-1.200)     0.003       23             1.139 (0.948-1.369)    0.023     23   1.221 (1.096-1.360)\*   0.219   23   0.995 (0.851-1.163)    0.025     23   1.203 (1.057-1.369)\*   0.064
  Ethnicity                                                                                                                                                                                                                        
  Asian                      17        1.107 (0.972-1.260)     0.001       17             1.196 (0.936-1.530)    0.007     17   1.191 (1.047-1.356)\*   0.487   17   1.035 (0.854-1.255)    0.011     17   1.197(1.023,1.401)\*    0.088
  Caucasian                  5         1.041 (0.909-1.193)     0.336       5              1.023 (0.779-1.343)    0.473     5    1.294 (0.906-1.848)     0.041   5    0.890 (0.696-1.138)    0.620     5    1.198 (0.888-1.618)     0.083
  African                    1         1.076 (0.790-1.464)     NA          1              1.065 (0.558-2.030)    NA        1    1.578 (0.951-2.620)     NA      1    0.793 (0.455-1.382)    NA        1    1.421 (0.877-2.301)     NA
  Source of controls                                                                                                                                                                                                               
  Hospital based             9         1.247 (1.022-1.523)\*   0.005       9              1.329 (0.924-1.912)    0.009     9    1.353 (1.115-1.642)\*   0.435   9    1.135 (0.871-1.479)    0.044     9    1.362(1.134,1.635)\*    0.116
  Population based           14        1.021 (0.941-1.107)     0.124       14             1.012 (0.832-1.231)    0.196     14   1.165 (1.024-1.327)\*   0.189   14   0.911 (0.764-1.087)    0.154     14   1.114(0.986,1.258)      0.190
  Sample size                                                                                                                                                                                                                      
  Small                      18        1.092 (0.955-1.249)     \<0.001     18             1.149 (0.896-1.472)    0.008     18   1.223 (1.036-1.445)\*   0.085   18   1.006 (0.813-1.246)    0.008     18   1.200 (1.006-1.430)\*   0.016
  Large                      5         1.032 (0.918-1.161)     0.269       5              1.051 (0.836-1.320)    0.313     5    1.134 (0.863-1.490)     0.042   5    0.980 (0.824-1.164)    0.810     5    1.107 (0.862-1.421)     0.052
  Cancer types                                                                                                                                                                                                                     
  Prostate cancer            2         0.993 (0.852-1.157)     0.385       2              0.993 (0.732-1.346)    0.331     2    1.039 (0.639-1.690)     0.081   2    0.985 (0.773-1.254)    0.896     2    1.027 (0.675-1.565)     0.109
  Esophageal cancer          2         1.095 (0.926-1.293)     0.852       2              1.111 (0.799-1.544)    0.783     2    1.371 (1.045-1.800)\*   0.528   2    0.945 (0.713-1.253)    0.591     2    1.289 (1.002-1.658)\*   0.700
  Nasopharyngeal carcinoma   4         1.144 (0.985-1.328)     0.845       4              1.305 (0.961-1.772)    0.759     4    1.330 (1.029-1.719)\*   0.704   4    1.082 (0.842-1.391)    0.547     4    1.323 (1.037-1.687)\*   0.823
  Colorectal cancer          3         1.066 (0.883-1.286)     0.262       3              1.092 (0.664-1.795)    0.213     3    1.460 (0.898-2.371)     0.097   3    0.896 (0.638-1.259)    0.359     3    1.337 (0.865-2.068)     0.118
  Breast cancer              2         1.147 (0.904-1.456)     0.726       2              1.332 (0.800-2.216)    0.438     2    1.169 (0.814-1.678)     0.532   2    1.225 (0.716-2.096)    0.274     2    1.204 (0.854-1.696)     0.784
  Cervical cancer            2         1.396 (0.208-9.382)     \<0.001     2              1.890 (0.069-51.901)   \<0.001   2    1.397 (0.644-3.031)     0.241   2    1.403 (0.090-21.882)   \<0.001   2    1.653 (0.241-11.339)    0.003
  Other cancers              8         1.044 (0.910-1.196)     0.200       8              0.978 (0.717-1.334)    0.223     8    1.100 (0.803-1.507)     0.014   8    0.935 (0.738-1.183)    0.804     8    1.075 (0.795-1.454)     0.012

OR: odds ratio; CI: confidence intervals; Phet: P value for heterogeneity; \* OR with statistical significance

Subgroup analyses, sensitivity analysis and cumulative meta-analysis {#s3.3}
--------------------------------------------------------------------

In a stratified analysis by specific cancer types, -607C/A polymorphisms in IL-18 gene promoter was significantly associated with an increased risk of nasopharyngeal carcinoma (CA vs CC:OR =1.330, 95% CI: 1.029,1.719; P~heterogeneity~=0.704; AA/CA vs. CC:OR =1.323, 95% CI: 1.037,1.687; P~heterogeneity~=0.823) and esophageal cancer(CA vs CC:OR =1.371, 95% CI: 1.045,1.800; P~heterogeneity~=0.528; AA/CA vs. CC:OR =1.289, 95% CI: 1.002,1.658; P~heterogeneity~=0.700) in the heterozygous model and dominant model. No evidence of association was found in any genetic model between-607C/A polymorphisms in IL-18 gene promoter and the risk of prostate cancer, colorectal cancer, breast cancer, cervical cancer, and other cancers(shown in [Table 2](#pone-0076915-t002){ref-type="table"}). According to ethnicity, the polymorphism presented a significantly increased risk of cancer among Asian population in the heterozygous model and dominant model(CA vs CC:OR =1.191, 95% CI: 1.047,1.356; P~heterogeneity~=0.487; AA/CA vs. CC:OR =1.197, 95% CI: 1.023,1.401; P~heterogeneity~=0.088); however, no significant association was found in Caucasian and African population (shown in [Table 2](#pone-0076915-t002){ref-type="table"}). In the stratified analysis by source of control groups, we found that the -607C/A polymorphisms in IL-18 gene promoter was associated with a significantly increased risk in hospital-based controls in the allelic model (A vs C:OR =1.247, 95% CI: 1.022, 1.523; P~heterogeneity~=0.005), heterozygous model(A vs C:OR =1.353, 95% CI: 1.115, 1.642; P~heterogeneity~=0.435), and dominant model(A vs C:OR =1.362, 95% CI: 1.134,1.635; P~heterogeneity~=0.116). However, among studies with population-based controls, a significant association was only observed in heterozygous model(A vs C:OR =1.165, 95% CI: 1.024, 1.327; P~heterogeneity~=0.189). When stratifying the sample size, a significant association was observed among studies with small sample size in the heterozygous model and dominant model (CA vs CC:OR =1.223, 95% CI: 1.036,1.445; P~heterogeneity~=0.085; AA/CA vs. CC:OR =1.200, 95% CI: 1.006,1.430; P~heterogeneity~=0.016), but not observed among studies with large sample size in any genetic models. To test the robustness of association, sensitivity analysis was carried out by excluding studies one-by-one and analyzing effect size for all of rest studies. Sensitivity analysis indicated that no significant variation in combined RR by excluding any of the study, confirming the stability of present results. Cumulative meta-analyses were carried out in the heterozygous and dominant genetic models. Between 2006 and 2013, with each accumulation of more studies, the 95% CIs for the pooled ORs became increasingly narrower, indicating that the precision of the estimation was progressively boosted by continually adding more samples(shown in [Figure 4](#pone-0076915-g004){ref-type="fig"}).

![Cumulative meta-analysis of association between -607C/A polymorphisms in IL-18 gene promoter and cancer risk under the heterozygous model(CA vs. CC).](pone.0076915.g004){#pone-0076915-g004}

Meta-regression and Publication bias {#s3.4}
------------------------------------

As shown in [Table 2](#pone-0076915-t002){ref-type="table"}, significant heterogeneity was present in all models except for heterozygous model, hence, meta-regression was conducted to detect the source of heterogeneity. Ethnicity, source of controls, sample size and cancer type, which may be potential sources of heterogeneity, were tested by a meta-regression method. The results showed that, in the dominant model (AA/CA vs. CC) for instance, the heterogeneity could only be explained by cancer type(p=0.014), but not ethnicity, sample size, or the source of controls. The potential publication bias of the literatures was evaluated by funnel plot and Egger's test. No visual publication bias was found in the funnel plot ([Figure 5](#pone-0076915-g005){ref-type="fig"}). And Egger's test suggested that no publication bias was detected in all the comparison models (P \>0.05)

![Funnel plot for publication bias in the studies investigating the association between -607C/A polymorphisms in IL-18 gene promoter and risk of cancer(heterozygous genetic model: CA vs. CC).\
No publication bias was observed among studies using Begg's P value (P = 0.167) and Egger's (P = 0.387) test, which suggested there was no evidence of publication bias.](pone.0076915.g005){#pone-0076915-g005}

Discussion {#s4}
==========

The present meta-analysis, which included 4100 cancer cases and 4327 controls from 21 publications with 22 case-control studies, explored the relationship between -607C/A polymorphisms in IL-18 gene promoter and cancer risk. For overall comparison of pooled ORs, significantly increased risk was observed in the heterozygous model(CA vs CC) and the dominant model(AA/CA vs. CC). Under the allelic, homozygous and recessive genetic models, there was no significant association between -607C/A polymorphisms in IL-18 gene promoter and cancer risk. Overall, a significant association exists between -607C/A polymorphisms in IL-18 gene promoter and cancer risk. This finding indicates that the genetic variant in IL-18 gene promoter region may crucially modify the susceptibility of cancers. The C to A substitution at position −607 disrupts a consensus cAMP-responsive element protein-binding site, causing altered transcription factor binding and gene expression \[[@B9]\]. IL-18 serum levels have been reported to be elevated in a variety of cancers compared with control group \[[@B19],[@B36]-[@B39]\]. Hence, the -607C/A polymorphisms in IL-18 gene promoter may modify the susceptibility of cancers though changing the expression of IL-18 gene. The mechanism needs further investigation.

When identifying eligible studies by reading full text, the study conducted by Jaiswal PK and colleagues \[[@B40]\] was excluded for incorrect data. The OR and 95% CI under heterozygous genetic model (OR =0.59, 95% CI: 0.39, 0.92)we got based on the genotype frequency in cases and controls(CC: 81, CA: 89 in cases; CC: 61, CA: 113 in controls) were totally opposed to that they got(OR =1.59, 95% CI: 1.01-2.95). Hence, we excluded this study for its unbelievable result.

In the stratified analysis based on ethnicity, a significant increased risk of cancer was found in Asian population, but not in Caucasian or African population. One probable reason is that different environment they live in and different genetic backgrounds may account for these differences. As we know, different populations carry different genotype and/or allele frequencies of this locus polymorphism and may lead to various degrees of cancer susceptibility \[[@B41]\]. And different ethnic groups live with multiple life styles and environmental factors and thus yield diverse gene-environment interactions \[[@B42]\]. In addition, there are only one study and five studies investigating the association between -607C/A polymorphisms in IL-18 gene promoter and cancer risk among African and Caucasian population, respectively. Insufficient number of patients limited us to detect stable effects in these two populations. Additional studies are warranted to further validate ethnic difference in the effect of -607C/A polymorphisms in IL-18 gene promoter on cancer risk, especially in Africans. During sub-group analyses, we found that the source of controls also affected the association between -607C/A polymorphisms in IL-18 gene promoter and cancer risk. A significant association was observed in hospital-based controls under allelic and dominant genetic models, but not the population-based controls. The reason may be that the hospital-based studies have some inherent selection biases as such controls may just represent a sample of ill-defined reference population and may not be very representative of the study population or the general population. In stratified analysis by cancer site, we found that -607C/A polymorphisms in IL-18 gene promoter was statistically related with an increased risk of esophageal cancer and nasopharyngeal carcinoma. However, no evidence of association was found in any genetic model between-607C/A polymorphisms in IL-18 gene promoter and the risk of prostate cancer, colorectal cancer, breast cancer, cervical cancer, or other cancers. One possible reason is that carcinogenic mechanism underlying the etiology may differ by different tumor sites and that the -607C/A polymorphisms in IL-18 gene promoter may play a different role in different cancers. Futher, the number of studies which investigated the association between -607C/A polymorphisms in IL-18 gene promoter and risk of different types of cancer was too small(≤3), which limited us to detect stable effects on different cancer types. So, more studies focusing on different cancer types are need in the future.

The strength of the present analysis lies in inclusion of 22 studies, reporting data of 4100 cancer cases and 4327 controls. Publication bias, which, due to the tendency of not publishing small studies with null results, was not found in our meta-analysis. Furthermore, our findings were stable and robust in sensitivity analyses. Cumulative meta-analyses showed that, with each accumulation of more studies, the 95% CIs for the pooled ORs became increasingly narrower, indicating that the precision of the estimation was progressively boosted by continually adding more samples. Some limitations might be included in the meta-analysis. Firstly, we did not search for unpublished studies, so only published studies were included in our meta-analysis. Therefore, publication bias may have occurred although no publication bias was indicated from both visualization of the funnel plot and Egger's test. Secondly, the results were based on unadjusted ORs, while a more precise estimation should take into account the effect of multiple confounders such as age, smoking status, drinking status and environmental factors on the association. Lack of information for data analysis may cause serious confounding bias. Thirdly, the small sample size is the major defect in this meta-analysis. In the stratified analysis by ethnicity and cancer type, the sample size of studies among Caucasians, Africans and among several cancer types is small, which limited us to detect stable effects in these populations and cancer types. Further studies are warranted to further evaluate the association in different ethnicities and cancer types in the future. Additionally, heterogeneity was significant in our meta-analysis, which may attenuate the strength of this study.

In conclusion, the present meta-analysis suggests that the -607C/A polymorphisms in IL-18 gene promoter is associated with a significantly increased risk of cancer, especially for nasopharyngeal carcinoma and esophageal cancer and in Asian population. More studies with larger sample size, well controlled confounding factors are warranted to further evaluate the association in different ethnicities and different cancer types in the future.
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